<DOC>
	<DOCNO>NCT02488408</DOCNO>
	<brief_summary>Multicenter open-label study BGB324 single agent combination cytarabine patient acute myeloid leukemia . BGB324 potent selective small molecule inhibitor Axl , surface membrane protein kinase receptor overexpressed half AML case .</brief_summary>
	<brief_title>Multicenter Open-label Study BGB324 Single Agent Combination With Cytarabine Patients With AML</brief_title>
	<detailed_description>This study dose-escalation cohort expansion study BGB324 , Axl kinase inhibitor , patient acute myeloid leukemia ( AML ) either single agent combination cytarabine . Study objectives include identify maximum tolerate dose ( MTD ) BGB324 AML patient receive previous treatment cytotoxic chemotherapy ( without haematopoietic stem cell transplantation ) target biologic agent . Identifying dose limit toxicity ( DLT ) profile BGB324 . To explore safety efficacy BGB324 characterise pharmacokinetic ( PK ) profile BGB324 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1 . Provision sign write informed consent 2 . Histological cytological confirmation AML ( exception AML M3 ) . 3 . Age 18 year old 4 . Female patient childbearing potential must negative serum pregnancy test within 3 day prior . Additional information Protocol . 1 . Patients match donor candidate allogeneic bone marrow transplantation 2 . Pregnant lactate 3 . Abnormal leave ventricular ejection fraction . 4 . History ischaemic cardiac event include myocardial infarction within 3 month study entry . Additional information Protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>